Paper38020221
Isolation and characterization of Trichoderma harzianum L-methioninase with promising a powerful anticancer.
Ashkan MF and 2 others. Saudi J Biol Sci, 2023. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Isolation and characterization of Trichoderma harzianum L-methioninase with promising a powerful anticancer. Papers, record 38020221. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38020221
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Isolation and characterization of Trichoderma harzianum L-methioninase with promising a powerful anticancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 5808079 | Dissimilation of methionine by fungi. | J Bacteriol | 1969 | https://conductscience.org/library/papers/5808079 | PubMed |
| 2 | 22883554 | Pharmacokinetics, immunogenicity and anticancer efficiency of Aspergillus flavipes L-methioninase. | Enzyme Microb Technol | 2012 | https://conductscience.org/library/papers/22883554 | PubMed |
| 3 | 37780 | Ellman's reagent: 5,5'-dithiobis(2-nitrobenzoic acid)--a reexamination. | Anal Biochem | 1979 | https://conductscience.org/library/papers/37780 | PubMed |
| 4 | 12367699 | Immunoenzymometric assay for recombinant methioninase in biological fluids. | J Pharm Biomed Anal | 2002 | https://conductscience.org/library/papers/12367699 | PubMed |
| 5 | 15328169 | Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/15328169 | PubMed |
| 6 | 20570523 | Glutamine addiction: a new therapeutic target in cancer. | Trends Biochem Sci | 2010 | https://conductscience.org/library/papers/20570523 | PubMed |
| 7 | 35093861 | Methionine Restriction: Ready for Prime Time in the Cancer Clinic? | Anticancer Res | 2022 | https://conductscience.org/library/papers/35093861 | PubMed |
| 8 | 3843705 | Measurement of protein using bicinchoninic acid. | Anal Biochem | 1985 | https://conductscience.org/library/papers/3843705 | PubMed |
| 9 | 26691554 | Purification, Characterization of L-Methioninase from Candida tropicalis, and Its Application as an Anticancer. | Biotechnol Res Int | 2015 | https://conductscience.org/library/papers/26691554 | PubMed |
| 10 | 11560998 | Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. | J Exp Med | 2001 | https://conductscience.org/library/papers/11560998 | PubMed |
| 12 | 36635695 | Purification, Characterization and anticancer activity of L-methionine γ-lyase from thermo-tolerant Aspergillus fumigatus. | Microb Cell Fact | 2023 | https://conductscience.org/library/papers/36635695 | PubMed |
| 13 | 15574935 | Identification and functional analysis of the gene encoding methionine-gamma-lyase in Brevibacterium linens. | Appl Environ Microbiol | 2004 | https://conductscience.org/library/papers/15574935 | PubMed |
| 14 | 32155163 | Diversity and antimicrobial activity of endophytic fungi isolated from Securinega suffruticosa in the Yellow River Delta. | PLoS One | 2020 | https://conductscience.org/library/papers/32155163 | PubMed |
| 15 | 12920135 | Identification and characterization of two isoenzymes of methionine gamma-lyase from Entamoeba histolytica: a key enzyme of sulfur-amino acid degradation in an anaerobic parasitic protist that lacks forward and reverse trans-sulfuration pathways. | J Biol Chem | 2003 | https://conductscience.org/library/papers/12920135 | PubMed |
| 16 | 10825143 | Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. | Cancer Res | 2000 | https://conductscience.org/library/papers/10825143 | PubMed |
| 17 | 21369990 | Purification and characterization of a new L-methioninase from solid cultures of Aspergillus flavipes. | J Microbiol | 2011 | https://conductscience.org/library/papers/21369990 | PubMed |
| 18 | 14585259 | Methionine dependency and cancer treatment. | Cancer Treat Rev | 2003 | https://conductscience.org/library/papers/14585259 | PubMed |
| 19 | 33370029 | Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model. | Pancreas | 2021 | https://conductscience.org/library/papers/33370029 | PubMed |
| 20 | 5432063 | Cleavage of structural proteins during the assembly of the head of bacteriophage T4. | Nature | 1970 | https://conductscience.org/library/papers/5432063 | PubMed |
| 21 | 2213904 | Methionine dependency of malignant tumors: a possible approach for therapy. | J Natl Cancer Inst | 1990 | https://conductscience.org/library/papers/2213904 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38020221
GET https://conductscience.org/api/papers/v1/38020221/references?page=2